Acute graft-versus-host disease in thalassaemic marrow transplantation with low-dose antithymocyte globulin

View/ Open
Abstract
Our unit performed transplantations on 21 classes II and III thalassaemic patients [class II patients had either hepatomegaly or portal fibrosis and class III patients had both]. We used busulfan [15 mg/kg] and cyclophosphamide [200 mg/kg]. Graft-versus-host disease [GVHD] prophylaxis was cyclosporin, prednisolone and low-dose antithymocyte globulin. Our patient data showed a low incidence of acute GVHD following transplantation. We offer this regimen as an acceptable therapy for thalassaemic patients undergoing allogeneic marrow transplantation as a safe clinical procedure, irrespective of the class of patientCitation
Khojasteh, H.N. (1999). Acute graft-versus-host disease in thalassaemic marrow transplantation with low-dose antithymocyte globulin. http://www.who.int/iris/handle/10665/118728
Relation
EMHJ - Eastern Mediterranean Health Journal, 5 (3), 465-469, 1999
Description
465-469ISSN
1020-3397Other Identifiers
http://applications.emro.who.int/emhj/0503/EMHJ_1999_5_3_465_469.pdfCollections
Language
EnglishMetadata
Show full item recordRelated items
Showing items related by title and MeSH subject.
-
Dura mater graft : association with Creutzfedt-Jakob disease
Unknown author (2004) -
Economics of coronary artery bypass grafting / Alan Williams
Williams, Alan (2001)